FealtySign in

Pfizer Inc.

(PFE)

CIK 78003 · SEC filings only

Not gradedDividend record
shown as history
company entity
20 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

20 declarations · 2 raised · 8 held · 0 cut

  1. INITIATED$0.8600/shperiod ended 2026-06-28Filing ↗
  2. INITIATED$0.8600/shperiod ended 2025-06-29Filing ↗
  3. INITIATED$0.8400/shperiod ended 2024-06-30Filing ↗
  4. INITIATED$0.8200/shperiod ended 2023-07-02Filing ↗
  5. NOTED$0.4000/shperiod ended 2022-10-02Filing ↗
  6. INITIATED$0.8000/shperiod ended 2022-07-03Filing ↗
  7. NOTED$0.3900/shperiod ended 2021-10-03Filing ↗
  8. INITIATED$0.7800/shperiod ended 2021-07-04Filing ↗
  9. HELD$0.3800/shperiod ended 2020-09-24Filing ↗
  10. HELD$0.3800/shperiod ended 2020-06-25Filing ↗
  11. HELD$0.3800/shperiod ended 2020-04-23Filing ↗
  12. RAISED$0.3800/shperiod ended 2019-12-13Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
Not yet gradedGuidance record
harness minimum not met
company entity
2 resolved promises

Not enough GAAP-comparable guidance to grade

2 of the 4 resolved guidance promises needed to publish a reliability grade. Much of this company’s guidance is non-GAAP, which has no comparable GAAP actual in SEC XBRL to check it against — shown below, never scored. Here's what we're tracking — we never show a grade we can't back with receipts.

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance shown, not graded (26)

These are non-GAAP forecasts. There is no comparable GAAP figure in SEC XBRL to check them against, so we show what was said — with its source filing — but never score it.

  1. eps guidance fy · Aug 4, 2026
    Reaffirms full-year 2026 Adjusted (3) diluted EPS guidance (2) in a range of $2.80 to $3.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. eps guidance fy · May 5, 2026
    Adjusted (4) Diluted EPS in a Range of $2.80 to $3.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Feb 3, 2026
    Adjusted (3) diluted EPS guidance (1) in a range of $2.80 to $3.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. eps guidance fy · Nov 4, 2025
    Raises and narrows Adjusted (2) diluted EPS guidance (1) to a range of $3.00 to $3.15
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. eps guidance fy · Aug 5, 2025
    Raises Full-Year 2025 Adjusted (2) Diluted EPS Guidance (1) by $0.10 to a Range of $2.90 to $3.10
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · Apr 29, 2025
    Adjusted (3) Diluted EPS in a Range of $2.80 to $3.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance fy · Feb 4, 2025
    Adjusted (3) Diluted EPS in a Range of $2.80 to $3.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · Oct 29, 2024
    raises Adjusted (2) diluted EPS guidance by $0.30 at the midpoint to $2.75 to $2.95
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. eps guidance fy · Jul 30, 2024
    raises Adjusted (2) diluted EPS guidance by $0.30 at the midpoint to $2.45 to $2.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · May 1, 2024
    Raises Adjusted (3) Diluted EPS Guidance to $2.15 to $2.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance fy · Jan 30, 2024
    2024 Adjusted (3) diluted EPS is anticipated to be in a range of $2.05 to $2.25
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. eps guidance fy · Oct 31, 2023
    Adjusted (3) Diluted EPS*  $1.45 to $1.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance fy · Oct 13, 2023
    the company now expects full-year 2023 Adjusted (2) diluted EPS to be in the range of $1.45 to $1.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  14. eps guidance fy · Aug 1, 2023
    maintaining its outlook for Adjusted diluted EPS (3) of $3.25 to $3.45
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. eps guidance fy · May 2, 2023
    Adjusted (3) Diluted EPS* $3.25 to $3.45
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. eps guidance fy · Jan 31, 2023
    Adjusted Diluted EPS (3) Guidance of $3.25 to $3.45
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  17. eps guidance fy · Nov 1, 2022
    Raises and Narrows Full-Year 2022 Adjusted Diluted EPS (3) Guidance from $6.30 to $6.45 to $6.40 to $6.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  18. eps guidance fy · Jul 28, 2022
    Range of $6.30 to $6.45
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  19. eps guidance fy · May 3, 2022
    Full-Year 2022 Financial Guidance (4) for Adjusted Diluted EPS (3) Revised to a Range of $6.25 to $6.45
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  20. eps guidance fy · Feb 8, 2022
    Adjusted Diluted EPS (3) $6.35 to $6.55
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  21. eps guidance fy · Nov 2, 2021
    Adjusted Diluted EPS (3) $2.60 to $2.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  22. eps guidance fy · Nov 2, 2021
    Adjusted Diluted EPS (3) $4.13 to $4.18
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  23. eps guidance fy · Jul 28, 2021
    Adjusted Diluted EPS (3) $3.95 to $4.05
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  24. eps guidance fy · May 4, 2021
    Adjusted Diluted EPS (2) $3.55 to $3.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  25. eps guidance fy · Feb 2, 2021
    Adjusted Diluted EPS (2) $3.10 to $3.20
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  26. eps guidance fy · Jul 29, 2019
    Adjusted Diluted EPS (2) $2.76 to $2.86
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗

Open promises (5) · 18 superseded

Open · revenue guidance fy

Revenues $45.0 to $46.0 billion

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

Raises Lower End of Full-Year 2022 Revenue Guidance (4) to a Range of $99.5 to $102.0 Billion

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

Pfizer raises full-year 2024 revenue guidance by $1.5 billion at the midpoint to a range of $61.0 to $64.0 billion

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

Reaffirms full-year 2025 Revenue guidance of $61.0 to $64.0 billion.

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

Raises full-year 2026 Revenue guidance (2) by $500 million at the midpoint to a range of $60.5 to $62.5 billion

resolves in ~202 daysreceipt →
Superseded · revenue guidance fy

Pfizer raises full-year 2024 revenue guidance by $1 billion at the midpoint to a range of $59.5 to $62.5 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Reaffirms Full-Year 2022 Financial Guidance (4) for Revenues of $98.0 to $102.0 Billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Reaffirms All Components of Full-Year 2025 Financial Guidance (1) , including Revenues in a Range of $61.0 to $64.0 Billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Reaffirms full-year 2026 Revenue guidance in a range of $59.5 to $62.5 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Reaffirms Full-Year 2025 Revenue Guidance (1) in a Range of $61.0 to $64.0 Billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

The company narrowed its 2023 revenue guidance (4) range to $67 to $70 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Provides Full-Year 2023 Revenue Guidance (4) of $67.0 to $71.0 Billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Pfizer Reaffirms Revenue Guidance of $98.0 to $102.0 Billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenues $59.4 to $61.4 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenues $98.0 to $102.0 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

The company still expects full-year 2024 revenues to be in the range of $58.5 to $61.5 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenues* $67.0 to $71.0 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Pfizer expects full-year 2024 revenues (2) to be in the range of $58.5 to $61.5 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenues $70.5 to $72.5 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Pfizer also announced that it now anticipates full-year 2023 revenues to be in the range of $58.0 to $61.0 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenues $78.0 to $80.0 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Revenues in a Range of $59.5 to $62.5 Billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Reaffirms All Components of Full-Year 2025 Financial Guidance (5) , including Revenues in a Range of $61.0 to $64.0 Billion

revised by a later guidancereceipt →

Credibility timeline

KEPT · Feb 24, 2022MISSED · Feb 22, 2024
20222024
Timeline as a list
  • Feb 24, 2022KEPTRevenues $81.0 to $82.0 billion
  • Feb 22, 2024MISSEDRevenues* $58.0 to $61.0 billion
2 resolved guidance promises · 26dropped (couldn't be resolved on a consistent basis) · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →